๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Predictors of skeletal complications in patients with metastatic breast carcinoma

โœ Scribed by Susan M. Domchek; Jerry Younger; Dianne M. Finkelstein; Michael V. Seiden


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
83 KB
Volume
89
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


Background:

The high rate of incidence of skeletal complications in women with metastatic breast carcinoma appears to contribute significantly to their morbidity. although recent trials have demonstrated the efficacy of bisphosphonates in preventing skeletal complications in selected patients, to the authors' knowledge the incidence rate of skeletal complications in an unselected population of women with metastatic breast carcinoma is unknown. the current study was designed to examine the incidence rate of skeletal complications in a large unselected group of women with metastatic breast carcinoma to determine predictors of these complications.

Methods:

All women (n = 718) diagnosed with metastatic breast carcinoma between 1981-1991 at the study institution were studied retrospectively.

Results:

Greater than 50% of the women developed skeletal complications; among these women, 51% had > 1 complication. approximately 80% of those with bone-limited disease at the time of diagnosis developed complications, as did 60% of those with bone and visceral disease and 21% of those with no bone disease. by univariate analysis, the site of initial metastatic disease, abnormal alkaline phosphatase, and a disease free interval of < 3 years were predictive of skeletal complications. multivariate analysis revealed that bone involvement at the time of diagnosis was predictive of subsequent skeletal complications.

Conclusions:

In this large retrospective study with extensive follow-up, skeletal complications were extremely common and repetitive, although complications predated patient death by >/= 1 year in the group of women presenting with any bone disease. the presence of bone disease at the time of initial presentation was predictive of skeletal complications. in this group of patients, the authors were unable to identify a subgroup with a low rate of skeletal complications.


๐Ÿ“œ SIMILAR VOLUMES


Fadrozole hydrochloride in postmenopausa
โœ Antonius A. Miller; Allan Lipton; I. Craig Henderson; Rudolph Navari; Mary T. Mu ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 471 KB ๐Ÿ‘ 1 views

## BACKGROUND. Fadrozole hydrochloride (CGS-16949A) belongs to the class of aromatase inhibitors that lowers circulating estrogen levels by inhibiting the conversion of androgens to estrogens, thereby causing tumor regression in patients with breast carcinoma. METHODS. This was a prospective, ran

CA 15-3 in patients with locoregional an
โœ J. G. Geraghty; E. C. Coveney; F. Sherry; N. J. O'Higgins; M. J. Dufy ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 341 KB ๐Ÿ‘ 1 views

Background. The value of circulating CA 15-3 levels was assessed in 129 patients with recurrent breast carcinoma. Methods. Patients were divided into four subgroups, according to the following: Group A, locoregional recurrence alone; Group B, locoregional and subsequent systemic recurrence; Group C

Predictors of axillary lymph node metast
โœ Andreas Barth; Pamela H. Craig; Melvin J. Silverstein ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 69 KB ๐Ÿ‘ 1 views

## Background: Axillary lymph node metastases (alnm) are the most important predictor of survival in patients with t1 breast carcinoma. due to a relatively low incidence of axillary metastasis in tumors < or = 2 cm, the role of axillary lymph node dissection for these patients has been questioned.